Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B6ADC
- Development stage
- Preclinical
- Lead developer
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
B6ADC is a preclinical bispecific nanobody-based antibody-drug conjugate (ADC) developed by the National Institute of Diagnostics and Vaccine Development in Infectious Diseases (Xiamen University). It is designed to simultaneously target Trophoblast cell-surface antigen 2 (TROP2) and Hepatocyte growth factor receptor (c-Met), which are frequently co-expressed in various solid tumors. The conjugate utilizes a bispecific nanobody to deliver the cytotoxic payload monomethyl auristatin E (MMAE) specifically to double-positive tumor cells, thereby enhancing selectivity and potentially reducing off-target toxicity. B6ADC is being investigated for the treatment of pancreatic cancer, lung adenocarcinoma, breast cancer, and colorectal cancer.
- Other names
- bispecific nanobody-ADCB6 ADC (MMAE payload)
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)MET (Mesenchymal-epithelial transition factor receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on B6ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B6ADC.